fig1

Unraveling <i>BRAF</i> alterations: molecular insights to circumvent therapeutic resistance across cancer types

Figure 1. Workflow of pan-cancer analysis of BRAF alterations across tumor types. Workflow of the analysis on the genomic data sets to evaluate - across multiple cancer types - the frequency of BRAF alterations (point mutations, deletions/amplifications and structural variants), associations with molecular/clinical features and mutational co-occurrence. Tumors were selected on a mutation frequency cutoff of 5% from the TCGA and non-TCGA datasets in cBioPortal. Cohort descriptions are provided in the main text and in the Methods section.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/